ImmVira's MVR-T3011 IT Injection Receives FDA Fast Track Designation
SHENZHEN, China, Nov. 9, 2023 /PRNewswire/ -- On November 9, 2023, ImmVira announced the successful completion of Phase I clinical study conducted on late-stage patients with various tumor types for our intravenous oncolytic product, MVR-T3011 IV, in the United States. This milestone was marked by the product's exceptional safety results and preliminary efficacy for certain indications. Concurrently, a series of comprehensive pharmacokinetics/pharmacodynamics (PK/PD) and immune responses research were also conducted, generating valuable firsthand data to guide the forthcoming Phase II clinical study.
SHENZHEN, China, Aug. 22, 2023 /PRNewswire/ -- ImmVira announced to appoint Dr. Howard L. Kaufman as Consulting Medical Advisor. Dr. Kaufman's expertise in scientific research and clinical development, especially in the areas of oncolytic virus and immunotherapy, will greatly enhance ImmVira's research and development capabilities.
SHENZHEN, China, June 6, 2023 /PRNewswire/ -- ImmVira submitted four abstracts covering latest results from Phase I/II clinical trials of MVR-T3011 IT (intratumoral injection) and MVR-T3011 IV (intravenous injection) in both U.S. and China with all selected to be published (1 chosen for poster discussion) at the 2023 American Society for Clinical Oncology Annual Meeting (ASCO 2023) taking place from June 2nd to 6th, 2023 in Chicago, IL.
SHENZHEN, China, Feb. 8, 2023 /PRNewswire/ -- ImmVira's first intratumoral injected OV product MVR-T3011 IT has shown positive efficacy in the course of clinical studies in the U.S. and China as of January 2023, with which the monotherapy treatment significantly prolonged PFS to a median of 12.9 months among melanoma patients who had failed previous immune-oncology treatment. Currently, late-stage melanoma faces poor prognosis. Clinical studies have found that median PFS of only 1.7 months for stage IV patients, second-line mono immunotherapy achieved median PFS of 2.8 and 3.6 months, combination therapy of PD-1 Ab and VEGF inhibitor achieved median PFS of 4.2 months.
SHENZHEN, China, Oct. 26, 2022 /PRNewswire/ -- ImmVira announced its successful signing of Series-C+ financing transaction documents with the first batch of investors recently. This round of financing was initiated by China Merchants China Direct Investments Limited with participation of Lifebay and Unifortune Group. To facilitate a number of ongoing follow investor's continued interest, the Company will keep the round open for a period of not more than two months. Interested investors can follow the agreed-on valuation and terms reached by lead investor and Company.
ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct...